[Management of anti-N-methyl-D-aspartate receptor encephalitis in children].
Zhongguo Dang Dai Er Ke Za Zhi
; 16(6): 584-8, 2014 Jun.
Article
en Zh
| MEDLINE
| ID: mdl-24927432
ABSTRACT
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a new category of severe, potentially treatable autoimmune encephalitis and can appear in patients of all ages, but more frequently in children. It is a highly characteristic syndrome evolving in five stages the prodromal phase (viral infection-like symptoms), psychotic phase, unresponsive phase, hyperkinetic phase, and gradual recovery phase. The treatment for this disorder includes first-line immunotherapy (steroids, intravenous immunoglobulin, plasmapheresis), second-line immunotherapy (rituximab, cyclophosphamide), and tumor removal. Hereby the progresses, selections and shortcomings of the treatment protocols for this disease are introduced.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Encefalitis Antirreceptor N-Metil-D-Aspartato
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Child
/
Humans
Idioma:
Zh
Revista:
Zhongguo Dang Dai Er Ke Za Zhi
Año:
2014
Tipo del documento:
Article
País de afiliación:
China